awaridii itọju akàn ẹdọfóró tuntun 2020

Ni ọdun 2020, awọn ilọsiwaju pataki ni a ṣe ni itọju akàn ẹdọfóró, pẹlu awọn ifọwọsi fun awọn itọju ibi-afẹde tuntun ati awọn ajẹsara, fifun awọn abajade ilọsiwaju ati awọn ọna ti ara ẹni fun awọn alaisan. Awọn ilọsiwaju wọnyi pese awọn aṣayan titun fun awọn ti o n koju akàn ẹdọfóró, ti n ba sọrọ awọn iyipada jiini kan pato ati igbelaruge esi ajẹsara ti ara lati ja arun na. Ọdun Ilọsiwaju: Bọtini Itoju Itọju Ẹdọfóró Tuntun 2020Ọdun 2020 samisi ọdun pataki kan ninu igbejako akàn ẹdọfóró. While the year was dominated by the global pandemic, researchers and clinicians continued to push the boundaries of treatment options. Several promising developments emerged, offering hope to patients and reshaping the landscape of lung cancer care. Shandong Baofa Cancer Research Institute ti tẹle awọn ilọsiwaju wọnyi ni pẹkipẹki. Awọn Itọju Itọju: Awọn Ilọsiwaju Oogun Itọkasi Awọn itọju ti a pinnu, ti a ṣe lati kọlu awọn ailagbara kan pato ninu awọn sẹẹli alakan, ri ilọsiwaju pataki ni 2020. Awọn itọju ailera wọnyi nigbagbogbo n fa awọn ipa-ipa diẹ sii ju kimoterapi ibile lọ nitori pe wọn fojusi awọn sẹẹli alakan diẹ sii ni pato.New Approvals for EGFR Mutations receptor (EGFR Mutations) akàn ẹdọfóró sẹẹli ti kii ṣe kekere (NSCLC). Ni ọdun 2020, awọn inhibitors EGFR tuntun ati ilọsiwaju ni a fọwọsi, nfunni ni iwalaaye ilọsiwaju ti o dara julọ fun awọn alaisan pẹlu awọn iyipada wọnyi. These newer-generation inhibitors often overcome resistance mechanisms that limit the effectiveness of earlier drugs. Ni pato, awọn aṣoju ti o fojusi awọn iyipada ifibọ EGFR exon 20 ṣe afihan iṣẹ-ṣiṣe ti o ni ileri.Fun apẹẹrẹ, ọkan iru oluranlowo jẹ amivantamab. Tabili ti o tẹle n ṣe afihan awọn abajade ti awọn idanwo ile-iwosan ti amivantamab: Oṣuwọn Idahun Apapọ Igbeyewo (ORR) Iye akoko Idahun (DoR) Ipele I 40% 11.1 osu Orisun: FDAALK Inhibitors: Expanding Treatment OptionsAnaplastic lymphoma kinase (ALK) rearrangements are another driver mutation in NSCLC. Ọpọlọpọ awọn inhibitors ALK ti wa tẹlẹ, ati ni ọdun 2020, iwadii dojukọ lori bibori atako si awọn oogun wọnyi ati idagbasoke awọn inhibitors ti o lagbara diẹ sii. Awọn itọju apapọ tuntun tun ṣe iwadii lati mu awọn abajade dara si ni ALK-positive ẹdọfóró akàn.Immunotherapy: Harnessing the Power of the Immune SystemImmunotherapy, which boosts the body’s ail system to combat a cancer, continue to be a major area of progress in ẹdọfóró akàn itọju ni 2020.Checkpoint Inhibitors in Earlier StagesCheckpoint inhibitors, ti o ni ipadasẹhin ti awọn inhibitors, itọju ti akàn ẹdọfóró to ti ni ilọsiwaju. In 2020, studies explored the use of these drugs in earlier stages of the disease, including after surgery or in combination with chemotherapy. Awọn ijinlẹ wọnyi fihan pe imunotherapy le mu awọn oṣuwọn iwalaaye dara si ati dinku eewu ti atunwi ni diẹ ninu awọn alaisan.Apapọ Immunotherapy RegimensResearchers tun ṣe iwadii apapọ awọn oogun ajẹsara ti o yatọ lati mu imudara wọn pọ si. Idinamọ ibi ayẹwo meji, ni lilo awọn oriṣiriṣi oriṣiriṣi meji ti awọn inhibitors checkpoint ajẹsara, fihan ileri ni diẹ ninu awọn alaisan ti ko dahun si ajẹsara-aṣoju-ẹyọkan. Awọn idanwo ile-iwosan tẹsiwaju lati ṣe atunṣe awọn ọna idapọpọ wọnyi lati ṣe idanimọ awọn alaisan ti o ṣeese julọ lati ni anfani.Ipa ti Igbeyewo BiomarkerAwọn ilọsiwaju ninu awọn itọju ti a fojusi ati awọn oogun ajẹsara ti ṣe afihan pataki ti idanwo biomarker okeerẹ ni akàn ẹdọfóró. In 2020, there was increased emphasis on testing for a wide range of genetic mutations and PD-L1 expression to guide treatment decisions. Ọna ti ara ẹni yii ṣe idaniloju pe awọn alaisan gba itọju ti o yẹ julọ ati ti o munadoko fun akàn wọn pato.Shandong Baofa Cancer Research Institute tẹnumọ pataki ti idanwo okeerẹ lati ṣe aṣeyọri awọn esi ti o dara julọ.Nwa iwaju: Awọn itọnisọna ojo iwajuThe awọn aṣeyọri itọju akàn ẹdọfóró tuntun 2020 pa ọna fun paapaa ilọsiwaju diẹ sii ni awọn ọdun ti n bọ. Iwadii ti nlọ lọwọ wa ni idojukọ lori idagbasoke awọn itọju ti a fojusi tuntun, imudarasi awọn ilana imunotherapy, ati idamọ awọn alamọ-ara tuntun. Ibi-afẹde ti o ga julọ ni lati ṣe agbekalẹ awọn itọju ti o munadoko diẹ sii ati ti ara ẹni ti o mu awọn oṣuwọn iwalaaye dara si ati didara igbesi aye fun gbogbo awọn alaisan ti o ni akàn ẹdọfóró.Ipari2020 jẹ ọdun ti awọn ilọsiwaju pataki ni itọju akàn ẹdọfóró. Awọn ifọwọsi ti awọn itọju ifọkansi tuntun ati awọn itọju ajẹsara, pẹlu itọkasi ti o pọ si lori idanwo biomarker, ti yi oju-ilẹ ti itọju akàn ẹdọfóró pada. Awọn aṣeyọri wọnyi funni ni ireti si awọn alaisan ati awọn idile wọn ati ṣe afihan pataki ti iwadii tẹsiwaju ati isọdọtun ninu igbejako arun apanirun yii. Gbé àbẹwò Shandong Baofa akàn Iwadi Institute ká oju opo wẹẹbu fun alaye diẹ sii lori awọn idanwo ile-iwosan ati awọn itọju alakan to ti ni ilọsiwaju.